Arizona Tribune - SOHM, Inc. Announces Patent Allowance/Approval in South Korea

This patent allowance is a significant milestone for SOHM Inc. as it expands its intellectual property portfolio in one of the largest and most dynamic markets in the world. The granted patent covers the utilization of our ABBIE gene editing technology for delivery of gene of interests into target cells or organisms. This supports licensing opportunities for the generation of novel cell therapies, and additional technologies in agriculture or biofuel, developed for commercialization. SOHM Inc's aim is to strengthen its competitive position in the global gene editing and cell therapy market valued at $ 7.96 billion and $ 4.74 billion respectively in 2023 (Grand View Research Market Reports).

"We are excited about the allowance of this patent in Korea, which underscores our commitment to innovation and our dedication to the future of targeted-integration technologies as the future of gene editing "said David Aguilar Ph.D. COO. "This development not only enhances our intellectual property strategy but also opens up new opportunities for collaboration and expansion within the Asian market."

The technology covered by the patent allowance is expected to facilitate the development of new cell therapies leading to possible cures for cancer and other congenital diseases. Technology will also lead to the development of safe sources of biofuel and support safe engineering of crops for human consumption.

For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.

About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.

For further information regarding this announcement or to explore potential collaborations, please contact:

SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: [email protected]
Phone: (714) 522-6700

Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.

SOURCE: SOHM, Inc

View the original press release on ACCESS Newswire

Y.Baker--AT